Any action aimed at lowering the chance of experiencing any unfavorable cardiovascular event is referred to as cardioprotection. This involves protecting the heart’s function by minimizing or averting harm, such as myocardial infarction and other consequences of ischemia or reperfusion.

Read More: cardioprotezione per il comune

A number of techniques that have been demonstrated to maintain the survival and function of cardiac muscle cell tissue after ischemia injury or reoxygenation are together referred to as cardioprotection. Three potential times points exist for the use of these strategies: prior to, during, and following an ischemia event (preconditioning), as well as during reperfusion (postconditioning).

Performing the intervention locally or remotely can lead to further stratification of cardioprotection. As a result, conditioning classes such as distant ischemia postconditioning, remote ischemic preconditioning, and remote ischemic postconditioning (RIPC) are created.

What are the causes of ischemia reperfusion injury (IRI)?

Worldwide, ischemic heart disease is thought to be the primary cause of mortality and disability. Acute ischemia reperfusion damage (IRI) leads to cardiomyocyte death, cardiac failure, arrhythmia development, and patient death. These outcomes are the aftermath of ischemic heart disease. This is counterintuitive since pumping blood to previously ischemic tissue—which is necessary to save what’s left—causes the heart to subsequently suffer harm. The primary goal of cardioprotective tactics is this.

The following clinical contexts include acute IRI of the heart:

Acute ST-segment elevation myocardial infarction (STEMI): primary percutaneous coronary intervention (PPCI) is performed to replace lost coronary blood flow in a patient experiencing acute myocardial ischemia from coronary artery blockage at the location of a ruptured atherosclerotic plaque. Myocardial reperfusion damage, a kind of cardiomyocyte mortality that occurs when the ischemic myocardium is reperfused, is now incurable.

ACS patient with ischemic heart disease receiving coronary artery bypass grafting (CABG)

Heart transplantation: in this case, despite efforts at cardioprotection, the heart is susceptible to extensive, real IRI.

It is still difficult to give instances for patient mobility and death in each of these substances. While a number of treatment approaches have been studied to counteract IRIs, the results have often been negative. Therefore, in order to restrict the amount of myocardial infarct and guarantee the preservation of heart function, new therapeutic approaches that focus on cutting-edge routes for cardioprotection are required. In doing so, the chance of the patient surviving is increased and heart failure is prevented from starting.

Cardioprotective substances and techniques

Numerous tactics were tried and failed in an attempt to protect the heart and reduce the extent of myocardial infarcts. The first attempts at cardioprotection were made more than 40 years ago, and although it is thought that therapeutic intervention can reduce the extent of the myocardial infarct, there is currently little evidence to support this theory—with early coronary artery profusion being a notable exception.

The following prospective cardioprotective medications have demonstrated promise when evaluated in clinical trials to decrease the size of myocardial infarcts or enhance ventricular function:

Utilizing adenosine

Hypothermia used therapeutically

Hypoxemic reperfusion: Patients with anterior acute myocardial infarction were reperfused in less than six hours, with no overall change seen.

Utilization of potassium, insulin, and glucose

Inefficient post-conditioning

A cyclosporine

ANP, or atrial natriuretic peptide

Kinase Cδ Inhibitor Protein

Next steps

Transferability of cardioprotection to humans is the most pressing direction that has to be pursued. Preclinical evidence must be gathered before a patient study may begin. Most significantly, the topic of cardioprotection has been confused by lack of repeatability. Since the prognosis of acute mycordial infarction, which affects around 1,000,000 Americans annually, is dependent on the extent of heart injury, it is thought that decreasing infarct size may lower the incidence of heart failure and lower death.